Law & policy

Latest content

Patent system should address “blind spot” around AI-generated inventions, KIPO commissioner says

In an exclusive interview with IAM, Kim Yong Rae says innovation will be discouraged if law fails to keep pace with technological change

09 November 2021

More than half a million Chinese patent applications swept up in quality crackdown so far

Reports say CNIPA identified 545,000 ‘abnormal’ patent applications in the first half of 2021 under new system set up to flag bogus filing activity

08 November 2021

IP rights are an important part of the push for more renewables

Saturday Opinion: IP protection is a significant driver of clean energy production, but it’s not the only key factor

06 November 2021

European plausibility uncertainties could be cleared up by new Enlarged Board of Appeal referral

The EPO is seeking clarity on a crucial question facing patentees, but not everyone is sure that a recent referral is the best vehicle

04 November 2021

Patent policy in the Biden era comes under the microscope at IAM event

Senior figures from InterDigital, Qualcomm, Dolby Labs and Novartis were among those who convened at IP 2021 to discuss the current administration’s IP priorities

03 November 2021

Leahy, Tillis blast “unseemly” patent litigation forum-shopping in letter to Chief Justice Roberts

Scathing missive aimed squarely at the Western District of Texas calls for study of “actual and potential abuses” enabled by single-judge divisions

03 November 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

Why a Russian patent injunction against 61 Samsung handset models could be a gamechanger

Exclusive analysis on the expansive legal theory used to bar use of Samsung Pay service and dozens of Galaxy smartphones

01 November 2021

Details of Kathi Vidal’s views on 101, the PTAB and much more besides begin to emerge

IAM reviewed the USPTO director nominee’s record and talked to people who have known her for decades to learn her stance on the most burning IP policy issues

28 October 2021

Biosimilars IP playbook is being re-written by the rise of interchangeables

Landmark designations highlight strategic IP ramifications of automatically-substitutable biosimilars

28 October 2021

Get unlimited access to all IAM content